News | January 21, 2010

Interventional Treatment Short-Circuits Hypertension

The Symplicity Catheter System manufactured by Ardian Inc. delivers radio frequency (RF) energy from within the renal artery to block conduction in the surrounding renal nerves.

January 21, 2010 – A new minimally invasive therapy using radiofrequency ablation to short-circuit nerves in the kidney arteries shows promise in treating uncontrolled hypertension. The research was presented this week at the International Symposium on Endovascular Therapy (ISET).

In a study of 70 patients, who had uncontrolled hypertension despite taking three or more blood pressure medications, underwent the procedure, called sympathetic renal denervation (RDN). One month after treatment, the average decrease in systolic blood pressure was 18 mmHg and in diastolic blood pressure was 11 mmHg. Blood pressure continued to improve, and the 34 patients who have reached 12-month follow-up had an average decrease in systolic blood pressure of 27 mmHg and in diastolic blood pressure of 11 mmHg.

“This treatment may help people who have the worst of the worst disease – who have hypertension that medications just can’t control and who are most likely to suffer from stroke and heart disease,” said Krishna Rocha-Singh, M.D., medical director of Prairie Vascular Institute, Springfield, Illinois, who is presenting results at ISET. “There are broader implications of this procedure, such as the possibility of using it to address other conditions, such as chronic kidney disease and heart failure. Another hope is that we eventually may be able to use this therapy to help patients with mild to moderate hypertension, without the use of drug therapy.”

Blood pressure is controlled by a combination of nerve signals and hormonal interactions between the brain, heart, blood vessels and kidneys. Hyperactive nerve signals from the kidneys may be a main cause of hypertension in many people. The nerves traveling to the kidneys are a key final common pathway needed to raise blood pressure. RDN treatment is used to interrupt these hyperactive signals between the kidney and the brain, leading to lower blood pressure. In the procedure, a tiny incision is made in the groin artery and a thin tube (catheter) with an electrode on the tip is inserted and advanced to the kidney arteries. The electrode is placed at up to six points along each artery, and low-dose radiofrequency energy is delivered to disable the surrounding nerves.

The kidneys play a central role in the long-term control of blood pressure, so the kidney is a major target of medicines used to control hypertension. However, more than a third of the 75 million Americans with hypertension are unable to control the condition, despite taking medication.

For more information: www.ISET.org

Related Content

The SERF VT EFS is a groundbreaking, single-arm observational study designed to evaluate the safety and effectiveness of the Thermedical Durablate catheter to treat VT. #HRS20 #HRS2020 #heartrhythm2020
News | Ablation Systems | May 08, 2020
May 8, 2020 – Results from a first-in-human early feasibility study (EFS) using a saline enhanced radiofrequency (SER
The Affera Inc. pulsed field (PF) energy radiofrequency ablation system. First-in-human trial shows new point-by-point approach provides increased flexibility and efficiency for physicians treating arrhythmia patients. #HRS #HRS2020 #HRS20 #heartrhythm20

The Affera Inc. pulsed field (PF) energy radiofrequency ablation system.

Feature | Ablation Systems | May 08, 2020
May 8, 2020 — A new clinical trial effectively uses pulsed field (PF) energy to treat patients with persistent or par
Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve